Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| BT-20 | Alvocidib | 1.0 | -0.5842 | 0.44635 |
| MDA-MB-157 | THZ531 | 0.316227766017 | -0.5831 | 0.30069 |
| AU565 | THZ1 | 1.0 | -0.5809 | 0.30331 |
| HCC1419 | LY3023414 | 10.0 | -0.5808 | 0.28511 |
| HCC1806 | THZ1 | 1.0 | -0.5805 | 0.54762 |
| MDA-MB-134-VI | THZ531 | 1.0 | -0.5803 | 0.18704 |
| HCC1500 | THZ531 | 0.0316227766017 | -0.5791 | -0.21452 |
| HCC1500 | Ulixertinib | 0.316227766 | -0.5791 | -0.11097 |
| SUM1315MO2 | THZ531 | 1.0 | -0.5746 | 0.18467 |
| HCC1428 | AZD2014 | 0.316227766 | -0.5733 | 0.03733 |
| MDA-MB-134-VI | THZ531 | 1.0 | -0.5715 | 0.17433 |
| HCC1395 | THZ531 | 1.0 | -0.5697 | 0.22733 |
| HCC1500 | Ribociclib | 0.01 | -0.5686 | -0.20506 |
| HCC1395 | MK 1775 | 10.0 | -0.5660 | 0.23444 |
| HCC1500 | RO-3306 | 3.16227766017 | -0.5633 | -0.16685 |
| SUM1315MO2 | MK 1775 | 10.0 | -0.5631 | 0.22832 |
| SK-BR-3 | THZ531 | 1.0 | -0.5625 | 0.31257 |
| HCC1428 | THZ1 | 0.316227766 | -0.5607 | 0.05417 |
| HCC1395 | MK 1775 | 10.0 | -0.5599 | 0.21866 |
| HCC1428 | GSK2334470 | 0.01 | -0.5581 | 0.02499 |
| SK-BR-3 | LY3023414 | 10.0 | -0.5571 | 0.13898 |
| HCC1428 | AZD2014 | 10.0 | -0.5555 | 0.02054 |
| CAL-85-1 | THZ1 | 1.0 | -0.5512 | 0.35477 |
| MDA-MB-361 | AZD2014 | 3.16227766017 | -0.5504 | 0.12661 |
| AU565 | Alvocidib | 1.0 | -0.5502 | 0.42491 |